The global neuroblastoma drugs market is driven by the increasing prevalence of neuroblastoma, a rare and aggressive childhood cancer that primarily affects children under the age of 5. According to the American Cancer Society, neuroblastoma accounts for about 6-10% of all cancers in children and approximately 15% of cancer-related deaths in this age group. The incidence of neuroblastoma is estimated to be around 1 in 100,000 live births annually, with a higher occurrence in children younger than 2 years old. The market is also influenced by advances in treatment options, including chemotherapy, immunotherapy, and targeted therapies. The approval of therapies such as Dinutuximab (Unituxin) and ongoing clinical trials for novel drugs are expanding the treatment landscape, offering new hope for patients. Additionally, the growing number of research initiatives focusing on genetic mutations, such as ALK gene alterations, is fueling the development of targeted treatments, further accelerating market growth.
